Meta-Analysis
Copyright ©The Author(s) 2024.
World J Clin Cases. Jun 26, 2024; 12(18): 3515-3528
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3515
Table 2 Odds ratio/mean difference (95% credible interval) results of the network meta-analysis
Clinical effective rate
SXN + OI
YQWX + OI
JPSX + OI
YQBX + OI
FFHY + OI
OI
SXB + OI0.78 (0.38, 1.60)0.97 (0.37, 2.58)1.03 (0.49, 2.18)0.70 (0.20, 2.45)1.76 (0.28, 11.22)0.23 (0.12, 0.43)
SXN + OI1.24 (0.55, 2.83)1.31 (0.77, 2.25)0.90 (0.29, 2.80)2.25 (0.38, 13.29)0.29 (0.21, 0.42)
YQWX + OI1.06 (0.45, 2.48)0.72 (0.19, 2.69)1.81 (0.27, 12.04)0.24 (0.11, 0.50)
JPSX + OI0.68 (0.21, 2.17)1.71 (0.29, 10.26)0.22 (0.15, 0.34)
YQBX + OI2.51 (0.32, 19.55)0.33 (0.11, 0.97)
FFHY + OI0.13 (0.02, 0.74)
Red blood cell levelSXN + OIYQWX + OIJPSX + OIYQBX + OIFFHY + OIOI
SXB + OI0.84 (0.34, 1.35)0.32 (-0.38, 1.01)-0.08 (-0.62, 0.45)0.05 (-0.78, 0.89)-0.27 (-1.32, 0.77)-0.67 (-1.10, -0.25)
SXN + OI-0.52 (-1.13, 0.08)-0.93 (-1.34, -0.51)-0.79 (-1.55, -0.03)-1.12 (-2.10, -0.13)-1.52 (-1.78, -1.26)
YQWX + OI-0.40 (-1.04, 0.23)-0.26 (-1.16, 0.64)-0.59 (-1.69, 0.50)-0.99 (-1.54, -0.45)
JPSX + OI0.14 (-0.65, 0.92)-0.19 (-1.20, 0.81)-0.59 (-0.91, -0.27)
YQBX + OI-0.33 (-1.52, 0.86)-0.73 (-1.44, -0.01)
FFHY + OI-0.40 (-1.35, 0.55)
Hemoglobin levelSXN + OIYQWX + OIJPSX + OIYQBX + OIFFHY + OIOI
SXB + OI17.40 (8.27, 26.54)5.34 (-7.00, 17.68)4.55 (-4.99, 14.09)12.87 (-0.40, 26.14)-1.66 (-17.20, 13.88)-11.25 (-18.94, -3.56)
SXN + OI-12.06 (-22.90, -1.22)-12.85 (-20.35, -5.35)-4.53 (-16.43, 7.36)-19.06 (-33.45, -4.68)-28.66 (-33.59, -23.72)
YQWX + OI-0.79 (-11.97, 10.40)7.53 (-6.97, 22.03)-7.00 (-23.60, 9.60)-16.59 (-26.25, -6.94)
JPSX + OI8.32 (-3.89, 20.53)-6.21 (-20.85, 8.43)-15.81 (-21.45, -10.16)
YQBX + OI-14.53 (-31.84, 2.78)-24.12 (-34.94, -13.30)
FFHY + OI-9.59 (-23.10, 3.92)
Serum ferritin levelSXN + OIYQWX + OIJPSX + OIYQBX + OIFFHY + OIOI
SXB + OI0.71 (-5.99, 7.41)8.16 (1.27, 15.05)-0.59 (-6.14, 4.96)1.29 (-7.20, 9.79)6.34 (-2.39, 15.08)-5.41 (-9.68, -1.15)
SXN + OI7.45 (-0.04, 14.94)-1.30 (-7.57, 4.98)0.59 (-8.39, 9.57)5.64 (-3.58, 14.85)-6.12 (-11.28, -0.95)
YQWX + OI-8.74 (-15.21, -2.28)-6.86 (-15.99, 2.26)-1.81 (-11.16, 7.53)-13.57 (-18.99, -8.15)
JPSX + OI1.88 (-6.28, 10.04)6.93 (-1.48, 15.34)-4.82 (-8.38, -1.26)
YQBX + OI5.05 (-5.54, 15.64)-6.71 (-14.05, 0.64)
FFHY + OI-11.75 (-19.38, -4.13)
Serum iron levelSXN + OIYQWX + OIJPSX + OIYQBX + OIFFHY + OIOI
SXB + OI4.31 (-0.28, 8.90)1.83 (-4.09, 7.74)3.48 (-1.79, 8.76)3.34 (-5.01, 11.68)0.64 (-7.85, 9.12)-3.03 (-7.19, 1.12)
SXN + OI-2.48 (-7.11, 2.15)-0.83 (-4.61, 2.95)-0.97 (-8.46, 6.52)-3.67 (-11.31, 3.97)-7.34 (-9.28, -5.40)
YQWX + OI1.65 (-3.65, 6.96)1.51 (-6.85, 9.87)-1.19 (-9.69, 7.31)-4.86 (-9.06, -0.66)
JPSX + OI-0.14 (-8.07, 7.78)-2.84 (-10.92, 5.23)-6.51 (-9.76, -3.27)
YQBX + OI-2.70 (-13.04, 7.64)-6.37 (-13.60, 0.86)
FFHY + OI-3.67 (-11.06, 3.72)
Adverse pregnancy outcomesSXN + OIYQWX + OIJPSX + OIYQBX + OIOI
SXB + OI0.79 (0.29, 2.12)1.33 (0.45, 3.92)0.72 (0.19, 2.63)1.41 (0.35, 5.63)3.04 (1.43, 6.48)
SXN + OI1.69 (0.62, 4.63)0.91 (0.26, 3.13)1.80 (0.48, 6.77)3.87 (2.03, 7.40)
YQWX + OI0.54 (0.15, 2.00)1.06 (0.26, 4.28)2.29 (1.05, 4.97)
JPSX + OI1.97 (0.41, 9.47)4.25 (1.47, 12.28)
YQBX + OI2.16 (0.68, 6.88)
Adverse eventsSXN + OIYQWX + OIJPSX + OIYQBX + OIFFHY + OIOI
SXB + OI0.46 (0.19, 1.10)1.03 (0.40, 2.68)0.93 (0.41, 2.13)0.29 (0.07, 1.11)2.32 (0.75, 7.20)1.47 (0.76, 2.86)
SXN + OI2.23 (0.89, 5.56)2.01 (0.92, 4.41)0.62 (0.16, 2.31)5.01 (1.71, 14.62)3.18 (1.84, 5.51)
YQWX + OI0.90 (0.36, 2.23)0.28 (0.07, 1.12)2.24 (0.69, 7.25)1.43 (0.69, 2.96)
JPSX + OI0.31 (0.08, 1.15)2.49 (0.85, 7.31)1.58 (0.91, 2.77)
YQBX + OI8.11 (1.79, 36.78)5.16 (1.55, 17.11)
FFHY + OI0.64 (0.25, 1.60)
OI: Oral iron; SXB: Shengxuebao Mixture; SXN: Shengxianning Tablet; YQWX: Yiqi Weixue Chinese patent medicines; JPSX: Jianpi Shengxue Chinese patent medicines; YQBX: Yiqi Buxue Tablets; FFHY: Compound Hongyi Buxue Oral Liquid.